Trial of Compassionate Use of hp802-247 to Treat Venous Leg Ulcers in Subjects Who Have Failed Multiple Other Healing Technologies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Compound HP802-247 comprises two topical sprays, administered sequentially right after another; these deliver a suspension of fibroblasts and keratinocytes to the wound surface. HP802-247 is the subject of a larger Phase 2 multi-center trial for treating venous leg ulcers. The present study will enroll up to five patients who are suffering venous leg ulcers, have failed a prolonged course of standard wound therapy and one or more advanced technologies, but who would not qualify for the Phase 2 study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

NCT01656889

Venous Leg Ulcers

COMPLETED PHASE3

Dose Finding Study of HP802-247 in Venous Leg Ulcers

NCT00852995

Venous Leg Ulcer Venous Stasis Ulcers

COMPLETED PHASE2

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

NCT01658618

Venous Leg Ulcer

UNKNOWN

Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247

NCT01970657

Venous Leg Ulcer (VLU)

COMPLETED

Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

NCT01853384

Venous Ulcer Venous Stasis Ulcer Ulcer

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Weekly HP802247 treatment

Group Type EXPERIMENTAL

Weekly wound spray with components 1 and 2 of the compound HP802-247

Intervention Type BIOLOGICAL

Weekly spray with HP802-247

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Weekly wound spray with components 1 and 2 of the compound HP802-247

Weekly spray with HP802-247

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic (duration greater than six months) open wound that has been diagnosed as a venous leg ulcer on the basis of consultation with a vascular surgeon and/or venous ultrasound evaluation
* Patient has been under continuous care at the Overlook Hospital Wound Healing Program for at least four months for treatment of the study lesion(s)
* Total study wound surface area greater than or equal to 12 cm2, but less than 48 cm2
* Wounds must have failed to heal despite the patient's compliance with elevation, compression and regular debridement, as well as at least one advanced wound therapy (for example, bioengineered dressing such as Oasis® or MatriStem®, low-frequency ultrasound, or cultured skin substitute (Apligraf®, Dermagraft®)
* Patient has no reasonable likelihood of healing with additional attempts to treat with FDA-approved products and treatments

Exclusion Criteria

* Patients eligible to participate in a Healthpoint sponsored clinical study of HP802-247 trial (IND 13,900)
* Patients who have been previously treated with HP802-247
* Women of child-bearing potential
* Patients who are allergic to any of the components of HP802-247

Eligible Sex

ALL

Accepts Healthy Volunteers

No